Second Affiliated Hospital of Wenzhou Medical University investigators have assessed the functions of FBXO28 on proliferation, migration and invasion in ovarian cancer.
Phyllodes tumors (PTs) are rare, fibroepithelial tumors of the breast that can arise as benign, borderline or malignant. Little is known about the molecular mechanisms behind their occurrence, and it is easy to misdiagnose them as other histologically similar tumors, such as metaplastic breast cancer. It was hypothesized that DNA methylation could be a helper here.
Chengdu Easton Biopharmaceuticals Co. Ltd. has identified cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.
Radiation therapy resistance (radioresistance) is a key contributor to the failure of rectal cancer treatment, with immunosuppression playing a significant role here.
23andme Holding Co. has received FDA clearance of its IND application for 23ME-01473 (‘1473), a dual mechanism antibody and natural killer (NK) cell activator intended to treat cancer.
Researchers from University of Lausanne have published data from a study that aimed to analyze the key components of the brain tumor vasculature in order to better understand the mechanisms of brain metastasis (BrM).
Researchers from Chengdu Zeling Biomedical Technology Co. Ltd. and affiliated organizations presented the discovery of novel phosphatidylinositol 3‑phosphate 5‑kinase (PIKfyve) inhibitors being developed for the treatment of cancer.
About 75% of patients with ovarian cancer are diagnosed with advanced disease. It is hence of high importance to explore reliable biomarkers and their mechanisms during pathology. Growing evidence exists regarding long noncoding RNAs (lncRNAs) as regulatory factors in several cellular processes.
RSS
